[ERCC1 as a Marker of Ovarian Cancer Resistance to Platinum Drugs] - PubMed

[Article in Russian]

• PMID: 26415382

Review

[ERCC1 as a Marker of Ovarian Cancer Resistance to Platinum Drugs]

[Article in Russian]

T A Bogush et al. Antibiot Khimioter. 2015.

Abstract

The review is concerned with the crucial marker of nucleotide excision repair ERCC1 and its contribution to platinum resistance of ovarian cancer. All the variants of the laboratory and clinical ERCC1 assessment in the ovarian cancer tissue (single nucleotide polymorphisms of the ERCC1 gene, levels of mRNA or protein) are considered. Data on the prognostic and predictive value of ERCC1 as a marker of the response to platinum-based therapy in ovarian cancer are systematized. The authors discuss the possible causes of heterogeneity of the results and emphasize the necessity of a unified and integrated approach to evaluation of ERCC1 in the tumor. The publications cited in the Search Engine Pub Med up to January 2015 were analyzed.

Similar articles

• Prediction of response to chemotherapy by ERCC1 immunohistochemistry and ERCC1 polymorphism in ovarian cancer.

  Steffensen KD, Waldstrøm M, Jeppesen U, Brandslund I, Jakobsen A. Steffensen KD, et al. Int J Gynecol Cancer. 2008 Jul-Aug;18(4):702-10. doi: 10.1111/j.1525-1438.2007.01068.x. Epub 2007 Oct 24. Int J Gynecol Cancer. 2008. PMID: 17961161 Clinical Trial.

• [Relationship between nucleotide excision repair gene ERCC1 and resistance to cisplatin in ovarian cancer].

  Liu GY, Qu QX, Mi RR, Qi J. Liu GY, et al. Zhonghua Zhong Liu Za Zhi. 2008 Mar;30(3):184-7. Zhonghua Zhong Liu Za Zhi. 2008. PMID: 18756932 Chinese.

• MZF1 possesses a repressively regulatory function in ERCC1 expression.

  Yan QW, Reed E, Zhong XS, Thornton K, Guo Y, Yu JJ. Yan QW, et al. Biochem Pharmacol. 2006 Mar 14;71(6):761-71. doi: 10.1016/j.bcp.2005.12.015. Epub 2006 Jan 19. Biochem Pharmacol. 2006. PMID: 16426580

• ERCC1 as a risk stratifier in platinum-based chemotherapy for nonsmall-cell lung cancer.

  Olaussen KA, Mountzios G, Soria JC. Olaussen KA, et al. Curr Opin Pulm Med. 2007 Jul;13(4):284-9. doi: 10.1097/MCP.0b013e32816b5c63. Curr Opin Pulm Med. 2007. PMID: 17534174 Review.

Cited by

• Genetic Variations and Cisplatin Nephrotoxicity: A Systematic Review.

  Zazuli Z, Vijverberg S, Slob E, Liu G, Carleton B, Veltman J, Baas P, Masereeuw R, Maitland-van der Zee AH. Zazuli Z, et al. Front Pharmacol. 2018 Sep 27;9:1111. doi: 10.3389/fphar.2018.01111. eCollection 2018. Front Pharmacol. 2018. PMID: 30319427 Free PMC article.

• Digoxin is a selective modifier increasing platinum drug anticancer activity.

  Bogush TA, Chernov VY, Dudko EA, Shprakh ZS, Bogush EA, Polotsky BE, Tjulandin SA, Davydov MI. Bogush TA, et al. Dokl Biochem Biophys. 2016 May;468(1):220-3. doi: 10.1134/S1607672916030170. Epub 2016 Jul 15. Dokl Biochem Biophys. 2016. PMID: 27417726

• The clinical value of aberrant epigenetic changes of DNA damage repair genes in human cancer.

  Gao D, Herman JG, Guo M. Gao D, et al. Oncotarget. 2016 Jun 14;7(24):37331-37346. doi: 10.18632/oncotarget.7949. Oncotarget. 2016. PMID: 26967246 Free PMC article. Review.

• A miR-15a related polymorphism affects NSCLC prognosis via altering ERCC1 repair to platinum-based chemotherapy.

  Xue P, Zhang G, Zhang H, Cui S, Zhang L, Yu T, Xiao M, Li L, Lu X. Xue P, et al. J Cell Mol Med. 2022 Nov;26(21):5439-5451. doi: 10.1111/jcmm.17566. Epub 2022 Sep 30. J Cell Mol Med. 2022. PMID: 36181289 Free PMC article.

• UBE2C Induces Cisplatin Resistance via ZEB1/2-Dependent Upregulation of ABCG2 and ERCC1 in NSCLC Cells.

  Wu Y, Jin D, Wang X, Du J, Di W, An J, Shao C, Guo J. Wu Y, et al. J Oncol. 2019 Jan 1;2019:8607859. doi: 10.1155/2019/8607859. eCollection 2019. J Oncol. 2019. PMID: 30693031 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Medical

  • MedlinePlus Health Information